Charles Russell Speechlys advises Kreos Capital and Silicon Valley Bank on £20 million growth capital investment in Mereo BioPharma
Charles Russell Speechlys have advised Kreos Capital and Silicon Valley Bank on a £20 million growth capital investment in Mereo BioPharma, a UK-based specialty bio-pharmaceutical company listed on the AIM market of the London Stock Exchange.
Mereo BioPharma was established to address the R&D and financial challenges faced by an increasing number of large pharmaceutical and biotech companies, and to optimise drug development and ensure that promising drug candidates fulfil their potential.
Mereo BioPharma announced to the market that it will use the financing to increase its operational and development flexibility.
The Charles Russell Speechlys core team comprised Chris Putt (Partner), Rossana Conti (Senior Associate), Amelly Kok (Associate) and Olivia Mackie (Associate) from our Corporate Team, and Daniel Sullivan (Partner) and Susan Mitchell (Senior Associate) from our Banking Team.”
News & Insights
Charles Russell Speechlys advises Vapotherm on the acquisition of Solus Medical
Vapotherm is a publicly traded developer and manufacturer of advanced respiratory technology.
Charles Russell Speechlys advises Daystar Power Group and founder on $10 million equity stake by Verod Capital Management and Persistent Energy
Daystar Power Group is a pan-African electricity company specialising in the generation of solar energy.
Charles Russell Speechlys advises FPE Capital and members of the management team of Kallidus on its sale
Kallidus is a leading human capital management and e-learning (SaaS) provider.
Charles Russell Speechlys Corporate team in Guildford shortlisted for four South East dealmakers awards
The awards celebrate the region’s corporate finance transactions across the legal, accountancy, banking and finance communities.